Skip to main content
Average ER Wait Times

Methodist Boerne Emergency Center

-- mins

Methodist Children's Hospital

-- mins

Methodist Hospital

-- mins

Methodist Specialty and Transplant Hospital

-- mins

Methodist Stone Oak Hospital

-- mins

Methodist Texsan Hospital

-- mins

Metropolitan Methodist Emergency Center at the Quarry

-- mins

Metropolitan Methodist Hospital

-- mins

Northeast Methodist Hospital

-- mins

Cancer Research Clinical Trials

The Methodist transplant team is committed to bringing you new and innovative investigational cancer treatment options.

One way we do this is by participating in cancer research trials and studies. Clinical trials provide patients with either the best treatment currently available or a new and possibly more effective therapy.

We encourage you to discuss your treatment options including research trials with your transplant doctor. Clinical trials are available for all stages of cancer, at MHS we offer clinical trials for:

Medical Management

For the most up to date information, visit clinicaltrials.gov.

Biological assessment of blood, marrow and solid tumors in patients with malignant disorders
Population: Adult, 18 years and older
Status: Open
Contact: 210-643-7218
Principal Investigator: Paul Shaughnessy, MD

SCRI AML 22: A Phase 1 Study of ASP2215 in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML
Population: Adult, 18 years and older
Status: Open
Contact: 210-241-0266
Principal Investigator: Jose Cruz, MD

AAML1031: A Phase III Randomized Trial for Patients with de novo AML using Bortezomib and Sorafenib for Patients with High Allelic Ratio FLT3/ITD
Population: Adult/Pediatric, less than 30 years old
Status: Open
Contact: 210-325-3803
Principal Investigator: Jaime Estrada, MD

SCRI AML 15: A Phase III, Randomized, Double Blind, Placebo Controlled Study to Compare Efficacy and Safety of Oral Azacytidine plus Best Supportive Care versus Best Supportive Care as Maintenance Therapy in Subjects with AML in CR
Population: Adult, 18 years and older
Status: Open
Contact: 210-241-0266
Principal Investigator: Jose Cruz, MD

SCRI AML 21: (KCP) Randomized, Open Label, Phase 2 of the Selective Inhibitor of the Nuclear Expor (ISONE) Selinexor (KPT 330) versus Specified Physician's Choice in Patients 60 year old with relapsed/refractory AML who are ineligible for intense chemotherapy
Population: Adult, 60 years and older
Status: Hold
Contact: 210-241-0266
Principal Investigator: Jose Cruz, MD

SCRI AML 29: Strategia Therapeutics: A Phase 1/2a study of E6201 for the treatment of advanced hematologic malignancies with FLT3 and/or Ras mutations, including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML)
Population: Adult, 18 years and older
Status: Pending
Contact: 210-317-9784
Principal Investigator: Jose Cruz, MD

Novartis: An open-label, multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in adult patients with newly diagnosed Fms-like tyrosine kinase receptor (FLT3) mutated Acute Myeloid Leukemia (AML) who are eligible for standard induction and consolidation chemotherapy
Population: Adult
Status: Pending
Contact: 210-317-9784
Principal Investigator: Jose Cruz, MD

Biological assessment of blood, marrow and solid tumors in patients with malignant disorders
Population: Adult, 18 years and older
Status: Open
Contact: 210-643-7218
Principal Investigator: Paul Shaughnessy, MD

AALL05B1: A Children's Oncology Group Protocol for Collecting and banking relapsed acute lymphoblastic leukemia research specimens
Population: Adult/Pediatric, 30 years or younger
Status: Open
Contact: 210-325-3803
Principal Investigator: Jaime Estrada, MD

AALL08B1: Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
Population: Adult/Pediatric, 30 years or younger
Status: Open
Contact: 210-325-3803
Principal Investigator: Jaime Estrada, MD

AALL1131: A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute ?Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum (Clofarabine Arm closed)
Population: Adult/Pediatric, 1-30 years old
Status: Open
Contact: 210-325-3803
Principal Investigator: Jaime Estrada, MD

AALL1231: A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy)
Population: Adult/Pediatric, 1-30 years old
Status: Open
Contact: 210-325-3803
Principal Investigator: Jaime Estrada, MD

AALL1331: Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
Population: Adult/Pediatric, 1-30 years old
Status: Open
Contact: 210-325-3803
Principal Investigator: Jaime Estrada, MD

Currently unavailable

Biological assessment of blood, marrow and solid tumors in patients with malignant disorders
Population: Adult, 18 years and older
Status: Open
Contact: 210-643-7218
Principal Investigator: Paul Shaughnessy, MD

ANHL1131: Intergroup Trial for Children or Adolescents with B-cell Non-Hodgkin Lymphoma NHL or Mature B-cell Leukemia B- AL: Evaluation of Rituximab (IND #10385) Efficacy and Safety in High Risk Patients
Population: Pediatric, 6 months to 17 years old
Status: Open
Contact: 210-325-3803
Principal Investigator: Jaime Estrada, MD

ALTE11C1: Longitudinal Assessment of Ovarian Reserve in Adolescents with Lymphoma
Population: Adult/Pediatric, females younger than 30 years old
Status: Open
Contact: 210-325-3803
Principal Investigator: Jaime Estrada, MD

SCRI LYM 111: KITE Pharma: A Phase 2 multicenter study evaluating the efficacy of KTE_C19 in subjects with relapsed/refractory Mantle Cell Lymphoma
Population: Adults 18 and older
Status: Pending
Contact: 210-643-7218
Principal Investigator: Paul Shaughnessy, MD

SCRI LYM 118: Merck: A phase III, randomized, open-label, clinical trial to compare Pembrolzumab with Brentuximab Vedotin in subjects with relapsed or refractory classical Hodgkins Lymphoma
Population: Adults 18 and older
Status: Pending
Contact: 210-643-7218
Principal Investigator: Seema Naik, MD

SCRI MM 51: A multicenter Phase 1/2b study of the Burton's tyrosine kinase inhibitor, Ibrutinib (PCI-32765), in combination with Carfilzomib (Kyprolis ™) in subjects with relapsed or relapsed and refractory multiple myeloma
Population: Adult, 18 years and older
Status: Pending
Contact: 210-643-7218
Principal Investigator: Paul Shaughnessy, MD

SRCI MM 72: Merck: MK3475PN183, A phase III study of Pomalidomide and Dexamethasone with or without Pembrolzumab in refractory or relapsed and refractory MM
Population: Adults 18 and older
Status: Pending
Contact: 210-643-7218
Principal Investigator: Seema Naik, MD

Transplant Trials

KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor
Population: Adult, 18 years and older
Status: Open
Contact: 210-643-7218
Principal Investigator: Paul Shaughnessy, MD

ASCT1221: A Randomized Phase II Study Comparing Two Different Conditioning Regimens Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) for Children with Juvenile Myelomonocytic Leukemia (JMML)
Population: Pediatric, 3 months to 17 years old
Status: Open
Contact: 210-325-3803
Principal Investigator: Jaime Estrada, MD

Mesoblast: A 1-Year, Multicenter, Randomized, Open-Label Controlled Study to Evaluate the Efficacy and Safety of Umbilical Cord Blood Cells Expanded Ex Vivo With Mesenchymal Precursor Cells for Hematopoietic Recovery in Patients With Hematologic Malignancy
Population: Adult/Pediatric, less than 65 years old
Status: Open
Contact: 210-325-3803
Principal Investigator: Paul Shaughnessy, MD

CTN 1101: Haplo versus Cord Transplant
Population: Adult, 18 years and older
Status: Open
Contact: 210-643-7218
Principal Investigator: Paul Shaughnessy, MD

SCRI BMT 16; Fate: A phase 1 non randomized/2 randomized study of ProTmune (ex vivo Programmed mobilized peripheral blood cells) for allogeneic hematopoietic cell transplantation in adult patients with hematologic malignancies
Population: Adult, 18 years and older
Status: Pending
Principal Investigator: Cesar Freytes, MD

Currently unavailable

MM 42: (Millennium) Open label study to determine the feasibility of MLN9708 as maintenance after allogeneic stem cell transplant for Multiple Myeloma followed by an expansion phase at the maximum tolerated dose
Population: Adult, 18 to 70 years and older
Status: Open
Contact: 210-643-7218
Principal Investigator: Paul Shaughnessy, MD

10-CBA: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units for transplantation in pediatric and adult patients with hematologic malignancies and other indications
Population: Adult/Pediatric, all ages
Status: Open
Contact: 210-325-3803
Principal Investigator: Robert Sanders, MD

SCRI HEM SUP 03: (Giliad) A phase 2b, randomized, double-blind, study evaluating antiviral effects, PK, safety and tolerability of GS-5806 in HCT recipients with RSV of the upper respiratory tract
Population: Adult, 18 to 75 years old
Status: Open
Contact: 210-643-7218
Principal Investigator: Seema Naik, MD

ACCL0933: A Randomized Open-Label Trial of Caspofungin versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)
Population: Adult/Pediatric, 3 months to 29 years old
Status: Open
Contact: 210-325-3803
Principal Investigator: Jaime Estrada, MD

COG ACCL0934: A randomized trial of levofloxacin to prevent bacteremia in children being treated for acute leukemia or undergoing hematopoietic stem cell transplantation
Population: Adult/Pediatric, 6 months to 20 years old
Status: Open
Contact: 210-325-3803
Principal Investigator: Jaime Estrada, MD

ACCL1034: Impact of Cleansing with Chlorhexidine Gluconate (CHG) on Reducing Central Line Associated Bloodstream Infection (CLABSI) and Acquisition of Multi-drug Resistant Organisms (MDRO) in Children with Cancer or Those Receiving Allogeneic Hematopoietic Cell Transplantation (HCT)
Population: Adult/Pediatric, 2 months to 20 years old
Status: Pending
Contact: 210-325-3803
Principal Investigator: Jaime Estrada, MD

COG ACCL1131: A Phase III Open-Label Trial of Caspofungin vs. Azole Prophylaxis for Patients at High-Risk for Invasive? Fungal Infections (IFI) Following Allogeneic Hematopoietic Cell Transplantation (HCT)
Population: Adult/Pediatric, 6 months to 20 years old
Status: Open
Contact: 210-325-3803
Principal Investigator: Jaime Estrada, MD

CMX001-351: An Intermediate-size, Expanded Access Protocol to Provide Brincidofovir for Treatment of Serious Adenovierus Infection or Disease.
Population: All ages
Status: Open
Contact: 210-687-6231
Principal Investigator: Troy Quigg, DO, MS

COG ACCL1131: A Phase III Open-Label Trial of Caspofungin vs. Azole Prophylaxis for Patients at High-Risk for Invasive? Fungal Infections (IFI) Following Allogeneic Hematopoietic Cell Transplantation (HCT)
Population: Ages 6 months to 21 years
Status: Open
Contact: 210-687-6231
Principal Investigator: Gerardo Quezada, MD

CTN 1203: Phase 2 trial of randomizing novel approaches for GVHD prevention compared to contemporary controls
Population: Adult, 18-75 years old
Status: Open
Contact: 210-643-7218
Principal Investigator: Behyar Zoghi, MD, PhD

Indiana University: A phase I study evaluating the addition of Bortezomib to an established acute graft versus host disease (aGVHD) prophylaxis regimen in pediatric allogeneic hematopoietic stem cell transplant (alloHSCT) patients
Population: Adult/Pediatric, 1-22 years old
Status: Pending
Contact: 210-325-3803
Principal Investigator: Troy Quigg, DO, MS

Mesoblast MESO 001: Remestemcel-L (Prochymal®), Ex-vivo Cultured Adult Human Mesenchymal Stem Cells for the Treatment of Acute GVHD
Population: Adult/Pediatric, 6 months to 75 years old
Status: Pending
Contact: 210-325-3803
Principal Investigator: Robert Sanders, MD

SCRI BMT 16; Fate: A phase 1 non randomized/2 randomized study of ProTmune (ex vivo Programmed mobilized peripheral blood cells) for allogeneic hematopoietic cell transplantation in adult patients with hematologic malignancies
Population:
Status:
Contact:
Principal Investigator:

Currently unavailable

Currently unavailable

PIDTC 6901: A prospective natural history study of diagnosis, treatment and outcomes of children with SCID disorders
Population: Pediatric, all ages
Status: Open
Contact: 210-325-3803
Principal Investigator: Troy Quigg, DO, MS

PIDTC 6903: Analysis of patients treated for chronic granulomatous disease since January 1, 1995
Population: Pediatric, all ages
Status: Pending
Contact: 210-325-3803
Principal Investigator: Troy Quigg, DO, MS

CIBMTR 13-TLEC: Natural History and Biology of Long-term late effects following Hematopoietic cell transplant for childhood hematologic malignancies
Population: Pediatric, 17 years and younger
Status: Pending
Contact: 210-325-3803
Principal Investigator: Troy Quigg, DO, MS

CTN: Haploidentical Transplantation in Aplastic Anemia
Population: Adult/Pediatric
Status: Pending
Contact: 210-325-3803
Principal Investigator: Robert Sanders, MD

SCI Outcomes 16: Evaluation of Patient Outcomes and Healthcare Economics in HSCT based on Donor typing by Insight KIR Profile™
Population: Adult, 18 years and older
Status: Pending
Principal Investigator: Behyar Zoghi, MD, PhD

Wash Univ HIT: A study of hematopoietic stem cell transplantation (HSCT) in immune function disorders using a reduced-intensity preparatory regimen (The HIT study)
Population: Ages 21 years and younger
Status: Open
Principal Investigator: Troy Quigg, DO, MS


How do clinical trials work?

Studies are broken down into different groups that each focus on certain things.

  • Phase 1 study investigates safety and side effects and the best dose of study drugs
  • Phase 2 determines the effectiveness and safety
  • Phase 3 looks at effectiveness, side effects and safety compared with other treatments
  • Phase 4 gathers more information after the Food and Drug Administration (FDA) approves the drug and it is on the market

Each cancer trial has a written detailed study design called a “protocol.” A protocol includes why the trial is needed, purpose of the trial, what drug or drugs are being tested and who can join the study. It also includes:

  • Safety measures
  • How outcomes will be measured
  • What information will be gathered about you

Standard Treatment

Standard treatment is treatment that experts agree is appropriate, accepted and widely used. As with any treatment, it will have side effects. For some blood cancers, the standard treatment may only be somewhat effective, in these instances, you may want to consider a clinical trial.

Randomization

This enables doctors to compare new treatments with standard treatments. Patients are divided into different groups at random. The “Control group” receives the best standard treatment available and the “Treatment group” receives the treatment under study. Sometimes a “placebo” maybe used, but rarely in cancer studies.

Placebo

A placebo is designed to look like the medicine being tested, but is not active. A study may compare standard treatment plus a new treatment, to standard treatment plus a placebo. You will be told if the study uses a placebo but you will not know if you are getting the placebo, nor will your study team, this is called “blinding” which allows the research team to look at your side effects without bias.